MIRA Pharmaceuticals (MIRA) Form 3 MIRA PHARMACEUTICALS / Christopher C Chapman JR ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Chapman Christopher C JR

(Last) (First) (Middle)

C/O MIRA PHARMACEUTICALS, INC.

900 WEST PLATT STREET, SUITE 200

(Street)

TAMPA FL 33606-2173

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/02/2023

3. Issuer Name and Ticker or Trading Symbol
MIRA PHARMACEUTICALS, INC. [ MIRA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Executive Chairman

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	200,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	(1)	06/15/2032	Common stock	220,000	5	D
Stock Option (right to buy)	(2)	04/28/2033	Common stock	60,000	5	D

Explanation of Responses:

1. The option vested and became exercisable as to 70,000 shares on June 15, 2022 and 50,000 shares on June 15, 2023. 50,000 of the remaining shares become exercisable on June 15, 2024 and 50,000 become exercisable on June 15, 2025.

2. The option vested and became exercisable as to 20,000 shares on April 28, 2023, and becomes exercisable on the remaining 20,000 shares on April 28, 2024 and 20,000 shares on April 28, 2025.

	/s/ Michelle Yanez, Attorney-in-Fact for Christopher C. Chapman, Jr.	08/02/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.